Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Mar;27(3):422–423. doi: 10.1128/aac.27.3.422

Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.

E J Goldstein, M L Alpert, B P Ginsberg
PMCID: PMC176290  PMID: 3158277

Abstract

In a prospective, randomized trial, norfloxacin (400 mg perorally, twice a day) was compared with trimethoprim-sulfamethoxazole (160-800 mg perorally, twice a day) in 45 patients with uncomplicated urinary tract infections. Escherichia coli was the most common isolate. Infections due to Enterobacter spp., Proteus mirabilis, Pseudomonas spp., and Staphylococcus spp. were also treated. Norfloxacin was equivalent in effectiveness and safety to trimethoprim-sulfamethoxazole, with a cure rate of 91% at the 5- to 9-day posttherapy visit and 88% at the 4- to 6-week posttherapy visit. It was well tolerated and had a low incidence of side effects.

Full text

PDF
422

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adhami Z. N., Wise R., Weston D., Crump B. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother. 1984 Jan;13(1):87–92. doi: 10.1093/jac/13.1.87. [DOI] [PubMed] [Google Scholar]
  2. Boppana V. K., Swanson B. N. Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography. Antimicrob Agents Chemother. 1982 May;21(5):808–810. doi: 10.1128/aac.21.5.808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Downs J., Andriole V. T., Ryan J. L. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Apr;21(4):670–672. doi: 10.1128/aac.21.4.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eandi M., Viano I., Di Nola F., Leone L., Genazzani E. Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage. Eur J Clin Microbiol. 1983 Jun;2(3):253–259. doi: 10.1007/BF02029528. [DOI] [PubMed] [Google Scholar]
  5. Giamarellou H., Tsagarakis J., Petrikkos G., Daikos G. K. Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur J Clin Microbiol. 1983 Jun;2(3):266–269. doi: 10.1007/BF02029530. [DOI] [PubMed] [Google Scholar]
  6. Guerra J. G., Falconi E., Palomino J. C., Benavente L., Antunez de Mayolo E. Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections. Eur J Clin Microbiol. 1983 Jun;2(3):260–265. doi: 10.1007/BF02029529. [DOI] [PubMed] [Google Scholar]
  7. Khan M. Y., Gruninger R. P., Nelson S. M., Klicker R. E. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates. Antimicrob Agents Chemother. 1982 May;21(5):848–851. doi: 10.1128/aac.21.5.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. King A., Warren C., Shannon K., Phillips I. In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother. 1982 Apr;21(4):604–607. doi: 10.1128/aac.21.4.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mitsuyasu R., Groopman J., Volberding P. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma. N Engl J Med. 1983 Jun 23;308(25):1535–1536. doi: 10.1056/NEJM198306233082512. [DOI] [PubMed] [Google Scholar]
  10. Panichi G., Pantosti A., Testore G. P. Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients. J Antimicrob Chemother. 1983 Jun;11(6):589–592. doi: 10.1093/jac/11.6.589. [DOI] [PubMed] [Google Scholar]
  11. Platt R., Polk B. F., Murdock B., Rosner B. Mortality associated with nosocomial urinary-tract infection. N Engl J Med. 1982 Sep 9;307(11):637–642. doi: 10.1056/NEJM198209093071101. [DOI] [PubMed] [Google Scholar]
  12. Shungu D. L., Tutlane V., Gadebusch H. H. Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin. J Clin Microbiol. 1983 Oct;18(4):988–991. doi: 10.1128/jcm.18.4.988-991.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wood S. J., Shadomy S. Disk diffusion susceptibility tests with norfloxacin: confirmation of proposed interpretive criteria. Eur J Clin Microbiol. 1983 Jun;2(3):242–244. doi: 10.1007/BF02029525. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES